An Update on the IDEOM (International Dermatology Outcome Measures) Initiative to Restructure Current Psoriasis Outcome Assessment Measures to a Globally Uniform Set of Patient-Centric Outcome Measures for Use in Clinical Trials and Clinical Practice

Abstract

The International Dermatology Outcome Measures (IDEOM) group was created with the goal of establishing improved, as well as patient-centered, outcome measures. The effort involves the worldwide participation of those involved in the treatment of psoriasis, including dermatologists, rheumatologists, pharmaceutical and device company medical officers, payors, regulatory officers, patient advocacy groups including the National Psoriasis Foundation, and patients themselves. This review will outline the work done to date, the methodology utilized, and future planned action, including a worldwide search for patient representatives to this endeavor.